From Grief to Global Research: A Mother's Fight Against Childhood Cancer

PHILADELPHIA, PA – June 11, 2026 – This Saturday, landmarks across Pennsylvania will glow blue and purple. The lights are for Elora Joyce Khan, a girl who loved blue butterflies and whose name means “Light of God.” It will be her 10th birthday. But Elora won’t be there to see it. She passed away from a relentless pediatric brain cancer three years ago, leaving a void her mother is now filling with purpose.

In an announcement that bridges devastating loss with determined hope, the Elora J. Khan Foundation has committed $10,000 to become the newest “Champion” of the Children's Brain Tumor Network (CBTN). The move unites a parent-led foundation born from tragedy with a global research consortium fighting on the front lines of pediatric neuro-oncology. It’s a small sum in the world of medical research, but it represents a monumental step in a new paradigm: one where families, not just institutions, are driving the quest for cures.

A Light Extinguished, A Movement Ignited

Elora Khan was a witty, vivacious seven-year-old first-grader when she was diagnosed with diffuse intrinsic pontine glioma, or DIPG. She fought for seven months before passing away in September 2023. Her mother, Sharon Pervez-Khan, refused to let Elora’s story end there. She founded the Elora J. Khan Foundation to transform her grief into action, channeling her daughter’s loving spirit into a multi-pronged mission.

The foundation’s work is a direct reflection of a child’s vibrant life cut short. It provides direct financial assistance to families navigating the same nightmare they endured. It organizes community events, like the “Cleats Out for Elora” charity soccer tournament that brought 30 teams together. In a profound extension of Elora’s legacy, the foundation even supports and has expanded an orphanage in Pakistan, now named “Elora’s Way Home of Hope,” caring for 31 children.

But at the core of its mission is a clear-eyed understanding of the enemy. “Joining CBTN as a Champion felt deeply aligned with the vision we have for the foundation because collaboration is essential in pediatric brain cancer research,” said Sharon Pervez-Khan in a statement. “For children facing aggressive brain tumors, time matters.”

The Unyielding Challenge of DIPG

Time is the one thing children with DIPG do not have. The disease is the leading cause of brain tumor-related death in children. It originates in the pons, a critical area of the brainstem that controls breathing, heart rate, and other essential functions. The tumor cells are not a solid mass that can be surgically removed; they are diffuse, weaving themselves into the delicate neural tissue. It is, for all intents and purposes, inoperable.

The prognosis has remained stubbornly, tragically unchanged for over 60 years. The median survival is less than a year. Radiation can offer a temporary reprieve, but it is not a cure. Chemotherapy has proven largely ineffective, blocked by the brain’s natural defense, the blood-brain barrier, and the tumor’s inherent resistance.

This devastating reality is compounded by a systemic failure in funding. All childhood cancers combined receive less than 4% of the federal government’s cancer research budget. A rare and complex disease like DIPG receives only a tiny fraction of that sliver. This leaves the heavy lifting to private institutions and, increasingly, to foundations like Elora’s—organizations fueled by an urgency that only personal experience can create.

Forging a Collaborative Front Line

This is where the Children’s Brain Tumor Network offers a new model of hope. Based at the Children's Hospital of Philadelphia, CBTN operates on a simple but revolutionary principle: no single institution can beat this disease alone. The network has built a global consortium of 32 member institutions that have agreed to pool their resources, breaking down the competitive silos that have historically slowed medical progress.

CBTN collects and harmonizes vast amounts of data—genomic, clinical, imaging—along with precious biological samples from patients. This information is then made available through cloud-based platforms to researchers anywhere in the world, free of charge. The network hosts what is now the largest open-access pediatric brain tumor dataset in existence, with integrated data from over 7,600 patients.

By becoming a CBTN Champion, the Elora J. Khan Foundation is not just writing a check. It is investing in an infrastructure of collaboration. It joins a coalition of over 20 other foundations, many also started by bereaved families, who collectively amplify their impact.

“The Elora J. Khan Foundation has transformed loss into meaningful action for children and families facing pediatric brain tumors,” said Gerri Trooskin, CBTN’s Director of Partnerships. “As a CBTN Champion, the Foundation strengthens a growing community committed to shared knowledge, collaborative research, and faster progress against these devastating diseases.”

A Birthday Remembered in Blue and Purple

On June 15, the advocacy born from Elora’s memory will become impossible to ignore. Elora Joyce Khan Pediatric Brain Cancer Awareness Day, officially recognized through resolutions by the Pennsylvania House and Senate and proclamations from Governor Josh Shapiro and Philadelphia Mayor Cherelle Parker, will turn the state into a beacon of remembrance. The Pennsylvania Capitol, Lincoln Financial Field, and landmarks across Philadelphia and Pittsburgh will be illuminated in blue and purple, Elora's favorite colors.

This statewide display is more than a memorial. It is a public demand for action and a visible symbol of solidarity for families who often suffer in silence. It is the culmination of a mother’s promise to honor her daughter, transforming a day of profound personal grief into a moment of powerful public awareness.

While the path is arduous, small glimmers of progress are beginning to emerge from this new collaborative landscape. The recent FDA approval of the first-ever drug for a subset of DIPG patients, dordaviprone, demonstrates that a deeper understanding of the tumor’s molecular biology can lead to targeted treatments. It’s a single step on a long road, but it’s a step that was unimaginable just a decade ago. For the families, researchers, and foundations on the front lines, it is proof that when they work together, they can begin to turn back the tide against an unforgiving disease.